oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Cervical Cancer Screening: oncgnostics Closes further Investment Round
Press ReleasesJena, October 17, 2018 – The Thuringian molecular diagnostics company oncgnostics, which quickly and successfully closed a 750,000 Euros crowd-investing round on Seedmatch early in 2018, now announces the closing […]
Oncgnostics GmbH retains Biotech Alliances International Inc. to support global partnering and distribution strategy.
Press Releases2018-10-02 San Francisco/Jena, Germany: Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Oncgnostics globalisation and partnering […]
Cervical Cancer and Uterine (Body) Cancer – What is the Difference?
BlogAlthough cervical cancer and uterine (body) cancer develop only a few centimetres apart, there are big differences in the cause of the disease. Therefore, the fields of research and treatment […]
oncgnostics in China: Pitch, Trade Fair, and Meeting with Partner
BlogDr. Martina Schmitz and Dr. Alfred Hansel, our CSO and CEO, have just come back from a visit in China, with days full of exciting events, dates and a few […]
Test for Uterine Cancer in Portugal: Biotech Firm oncgnostics Grants Exclusive Licence for Cancer Screening Test
Blog, Press ReleasesLisbon/Jena, April 16th 2018 – Speculum S.A. is the exclusive licence partner of oncgnostics GmbH for the screening test GynTect® in Portugal. The test is designed to further specify abnormal […]
Reliable test for cervical cancer triage now available in Slovakia and the Czech Republic: Biotech company oncgnostics concludes an exclusive partnership with the MEDIREX group
Blog, Press ReleasesJena, January 31th 2018 – oncgnostics GmbH partners with the MEDIREX Group. MEDIREX thus holds the exclusive rights for marketing the test for early and reliable detection of cervical cancer, […]
GynTect soon available in China: – oncgnostics grants exclusive license for GynTect to the Chinese SINOPHARM subsidiary CJMT – approval for the Chinese market planned
Blog, Press ReleasesJena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) […]
oncgnostics presents extended version of its cervical cancer diagnostics test GynTect at MEDICA
Press ReleasesJena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of […]
Early detection of cervical cancer: „GynTect 2.0“- wider range of application by using a greater variety of patient samples
Press ReleasesJena, September 20th, 2016 – GynTect, a molecular diagnostic test developed by the biotech company oncgnostics, allows fast and reliable diagnostics of cervical cancer and the corresponding precancerous stages. The […]
An investment into life: we start a crowdfunding campaign via the platform Seedmatch – with prominent support!
BlogThose who have once been suspected to suffer from a severe disease know all-too-well, how long and grueling it can be to wait for further examinations that might bring clarity. […]